Dahong Li1, Xu Hu2, Tong Han3, Jie Liao4, Wei Xiao5, Shengtao Xu6, Zhanlin Li7, Zhenzhong Wang8, Huiming Hua9, Jinyi Xu10. 1. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. lidahong0203@163.com. 2. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. huxu105@163.com. 3. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. hantong1221@163.com. 4. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. howlris@gmail.com. 5. State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Processes, National Post-Doctoral Research Workstation, Jiangsu Kanion Pharmaceutical Co. Ltd., Lianyungang 222001, China. kanionxw2010@126.com. 6. State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China. cpuxst@163.com. 7. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. lzl1030@hotmail.com. 8. State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Processes, National Post-Doctoral Research Workstation, Jiangsu Kanion Pharmaceutical Co. Ltd., Lianyungang 222001, China. kanionwzz2016@126.com. 9. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. huimhua@163.com. 10. State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China. jinyixu@china.com.
Abstract
A series of nine enmein-type ent-kaurane diterpenoid and furoxan-based nitric oxide (NO) donor hybrids (10a-i) were designed and synthesized from commercially available oridonin (1). These hybrids were evaluated for their antiproliferative activity against Bel-7402, K562, MGC-803, and CaEs-17 human cancer cell lines and L-02 normal liver cells. The antiproliferative activity against tumor cells was stronger than the lead compound 1 and parent molecule 9 in most cases. Especially, compound 10f showed the strongest activity against human hepatocarcinoma Bel-7402 cell line with an IC50 of 0.81 μM and could also release 33.7 μmol/L NO at the time point of 60 min. Compounds 10a-i also showed cytotoxic selectivity between tumor and normal liver cells with IC50 ranging from 22.1 to 33.9 μM. Furthermore, the apoptotic properties on Bel-7402 cells revealed that 10f could induce S phase cell cycle arrest and apoptosis at low micromolar concentrations. The effects of 10f on apoptosis-related proteins were also investigated. The potent antiproliferative activities and mechanistic studies warrant further preclinical investigations.
A series of nine enmein-type ent-kauranediterpenoid and furoxan-based nitric oxide (NO) donor hybrids (10a-i) were designed and synthesized from commercially available oridonin (1). These hybrids were evaluated for their antiproliferative activity against Bel-7402, K562, MGC-803, and CaEs-17 humancancer cell lines and L-02 normal liver cells. The antiproliferative activity against tumor cells was stronger than the lead compound 1 and parent molecule 9 in most cases. Especially, compound 10f showed the strongest activity against human hepatocarcinoma Bel-7402 cell line with an IC50 of 0.81 μM and could also release 33.7 μmol/L NO at the time point of 60 min. Compounds 10a-i also showed cytotoxic selectivity between tumor and normal liver cells with IC50 ranging from 22.1 to 33.9 μM. Furthermore, the apoptotic properties on Bel-7402 cells revealed that 10f could induce S phase cell cycle arrest and apoptosis at low micromolar concentrations. The effects of 10f on apoptosis-related proteins were also investigated. The potent antiproliferative activities and mechanistic studies warrant further preclinical investigations.
Entities:
Keywords:
NO donor; antiproliferative activity; apoptosis related proteins; diterpenoid; oridonin
Natural products and natural product structures continue to play a highly significant role in the drug discovery and development process, especially in the case of antitumor drugs [1]. Diterpenoids, especially ent-kauranediterpenoids, are well known to produce bioactive molecules [2]. Among these, enmein-type 6,7-seco-ent-kaurane diterpenoids have unique chemical skeletons and exhibit significant activities (Figure 1) [3,4,5]. These natural enmein-type ent-kauranediterpenoids with a lot of stereogenic centers and complex ring systems have attracted much attention [6,7,8,9,10,11,12,13,14,15]. Natural sources cannot afford large compound supply for structure modification. We have found a convenient and feasible method to construct the skeleton of enmein-type 6,7-seco-ent-kauranediterpenoid from natural oridonin [9]. Further investigation in the field of medicinal chemistry is still in urgent need.
Figure 1
Natural enmein-type ent-kaurane diterpenoids.
Nitric oxide (NO), one of the simplest, odorless, colorless, highly reactive, and biological molecules in nature, is a free radical and a key mediator involved in diverse physiological and pathological processes [16,17,18,19,20]. NO-donating compounds have recently come into focus for the treatment of tumors because NO plays a central role in cell regulatory pathways and is a key signaling molecule involved in the death and apoptosis of tumor cells [21,22,23,24,25,26,27,28,29,30,31,32]. Generally, high levels of NO (above 400 nM [33]) produced from NO donors can induce apoptosis, inhibit metastasis of tumor cells, and sensitize tumor cells to radiation, immunotherapy, and chemotherapy. Some synthesized NO-releasing compounds have already shown antitumor activity against humancarcinoma cells in vitro and in vivo [21,22,23,24,25,26,27,28,29,30,31,32]. Due to the highly reactive nature of NO, it is difficult to predict its biological effects on a given system from single doses even if provided by the longer action of inducible nitric oxide synthase (iNOS). High concentrations of NO can be generated not only by iNOS, stimulated by cytokines, but also effectively by NO donors. Thus, NO donors, capable of producing a sustained release with a wide range of half-time lives and predictable estimated doses, have become useful tools to study the biological properties of NO in cells and in vivo models of carcinogenesis [34]. Furoxans are stable and represent an important class of NO donors, which can produce high levels of NO in vitro and inhibit the growth of tumors in vivo. The furoxan ring releases NO with the action of thiol cofactors [23]. It is hypothesized that furoxan-ring opening to give a nitroso derivative is accomplished by thiolate attacking position 3 or 4. The derivative then releases NO−, which is oxidized to release NO [35,36,37]. The ester molecules characterized by a furoxan-based NO-releasing moiety have already been explored by several research groups for improving the pharmacological profile of the parent drugs [26,38,39,40]. For example, Chen et al. synthesized a series of furoxan-based NO-releasing oleanolic acid derivatives [41]. Six derivatives exhibited strong antiproliferative activity in vitro and released high levels of NO, and two of them showed significant inhibitory activity of humanhepatocellular carcinomatumor in vivo. The hybrids with glycyrrhetinic acid were achieved by Lai et al. [42]. Five derivatives showed small IC50 values against humanhepatocellular carcinomatumor cells (0.25–1.10 μM against Bel-7402 cells and 1.32–6.78 μM against HepG 2 cells). At the same time, the selectivity between tumor and normal cells was observed, since low antiproliferative activity was obtained against the L-02 cell line. Besides, the anticancer potency of triterpenoid/furoxan-based NO-donating analogues against multidrug-resistant cancer cells was also developed by Zhang’s group [32,43]. Some furoxan-based NO donor/coumarin [40] and diterpenoid [44] hybrids were also developed as antitumor agents. So, the synthesis of natural product/NO donor derivatives is the feasible approach to get promising anticancer candidates.The reasons above stimulated us to combine two of our molecules of interest together. So, a series of furoxan-based NO-releasing enmein-type ent-kauranediterpenoid derivatives were developed. The antiproliferative activity of these hybrids was tested against four humancancer cell lines (Bel-7402hepatoma, K562leukemia, MGC-803 gastric cancer, and CaEs-17 esophageal cancer cells) and normal liver L-02 cells. The NO-releasing ability was measured by Griess assay. Then the preliminary structure activity relationship (SAR) was concluded based on these experimental data. Furthermore, the investigation of molecular mode of action and effects on apoptosis-related proteins in Bel-7402 cells was also carried out.
2. Introduction
2.1. Synthesis of Compounds and
The synthesis routine is illustrated in Scheme 1. The starting material benzenethiol (2) was converted to diphenylsulfonylfuroxan (5) in a three-step sequence. Monophenylsulfonylfuroxans (6a–c) were synthesized through the reactions of 5 by treatment with corresponding diols (ethane-1,2-diol, propane-1,3-diol, and butane-1,4-diol). Finally, different anhydrides (succinic anhydride, glutaric anhydride, and phthalic anhydride) were reacted with 6a–c to obtain the key intermediate furoxan-based NO donors 7a–i [45]. Starting from commercially available ent-kauranediterpenoidoridonin (1), enmein-type 6-oxo-6,7-seco-kaurane diterpenoid (9) was obtained by two steps of oxidation in total yields of 87% [10]. Compound 9 was reacted with furoxan-based NO donors 7a–i to produce target hybrids 10a–i.
2.2. Antiproliferative Activities in Vitro and SAR
The antiproliferative activity of 7a–i and 10a–i was evaluated using the MTT method against Bel-7402, L-02, K562, MGC-803, and CaEs-17 cell lines. The results are summarized in Table 1. Compounds 7a–i exhibited stronger antiproliferative activity against four selected tumor cell lines than in normal liver cell line L-02, with IC50 values ranging from 16.7 to 25.7 μM. Compounds 7d–f with R1 of (CH2)3 exhibited stronger cytotoxicity in tumor cells than those with R1 of (CH2)2 and (CH2)4. From these data, no obvious SAR could be concluded when R2 was changed among (CH2)2, (CH2)3, and o-C6H4. It was also found that all the target derivatives 10a–i exerted stronger antiproliferative activities than the lead oridonin against all four selected tumor cells and parent compound 9 against Bel-7402, MGC-803, and CaEs-17 cancer cell lines. In K562 cells, the IC50 values of 10a–i ranged from 1.73 to 2.90 μM, while parent compound 9 showed IC50 value of 2.64 μM. The target compounds 10 exhibited more potent cytotoxic activity than corresponding NO donors 7, which was also consistent with the literature [46]. Compounds 10a–c had the same R1 of (CH2)2, and R2 were (CH2)2, (CH2)3, and o-C6H4, respectively. Among them, 10c with R2 of o-C6H4 showed the strongest in vitro antiproliferative activity with IC50 values of 1.01, 1.97, 1.60, and 4.02 μM against Bel-7402, K562, MGC-803, and CaEs-17 cell lines, respectively. Similar SAR could also be concluded from 10d–f and 10g–i, that R2 of o-C6H4 was favorable. In general, when R2 were aromatic groups o-C6H4 (10c, 10f and 10i), the antiproliferative potency was stronger than those of alkyl groups. Compounds 10a, 10d, and 10g bearing the same R2 of (CH2)2 and 10d with R1 of (CH2)3 exhibited smaller IC50 values against the four cancer cell lines. In group 10b, 10e, and 10h, and group 10c, 10f, and 10i, similar SAR could also be observed that 10e and 10f with R1 of (CH2)3 showed stronger cytotoxic activity.
Table 1
The antiproliferative activity (IC50
a μM) of synthetic hybrids 10a–i against selected cell lines b.
Compound
Bel-7402
L-02
K562
MGC-803
CaEs-17
1
7.48 ± 0.32
18.3 ± 0.8
4.76 ± 0.32
5.69 ± 0.39
11.0 ± 1.0
9
16.0 ± 1.1
26.4 ± 1.3
2.64 ± 0.19
5.84 ± 0.57
23.7 ± 1.8
7a
22.0 ± 0.8
37.8 ± 1.3
22.6 ± 2.0
25.4 ± 1.5
24.3 ± 0.9
7b
22.3 ± 1.6
39.6 ± 1.4
24.2 ± 2.5
22.2 ± 2.5
25.7 ± 1.4
7c
19.6 ± 1.0
41.3 ± 2.9
22.6 ± 1.7
24.6 ± 1.4
23.8 ± 1.0
7d
17.8 ± 1.4
37.4 ± 0.8
17.5 ± 1.4
18.5 ± 0.8
19.8 ± 1.3
7e
18.6 ± 0.8
36.3 ± 2.1
18.5 ± 1.6
20.0 ± 1.1
18.7 ± 1.0
7f
16.7 ± 0.8
35.8 ± 1.3
17.5 ± 1.0
19.3 ± 0.6
19.2 ± 0.7
7g
22.7 ± 1.0
39.4 ± 2.6
24.0 ± 1.4
20.6 ± 1.7
25.7 ± 0.7
7h
21.3 ± 0.7
35.4 ± 1.4
24.5 ± 1.4
23.5 ± 1.0
22.9 ± 1.4
7i
22.4 ± 1.6
37.9 ± 2.8
23.0 ± 1.2
21.6 ± 1.5
24.8 ± 1.5
10a
1.91 ± 0.09
24.4 ± 0.8
2.86 ± 0.05
2.84 ± 1.12
5.68 ± 0.53
10b
1.75 ± 0.12
22.1 ± 1.3
2.90 ± 0.17
2.67 ± 0.24
5.56 ± 0.06
10c
1.01 ± 0.04
31.2 ± 1.2
1.97 ± 0.18
1.60 ± 0.15
4.02 ± 0.14
10d
1.17 ± 0.02
27.4 ± 1.0
2.04 ± 0.10
2.03 ± 0.15
4.84 ± 0.47
10e
1.12 ± 0.09
29.3 ± 0.9
2.02 ± 0.17
1.91 ± 0.09
4.04 ± 0.23
10f
0.81 ± 0.06
29.9 ± 1.4
1.73 ± 0.04
1.18 ± 0.10
3.77 ± 0.30
10g
1.85 ± 0.11
33.9 ± 1.5
2.82 ± 0.22
2.80 ± 0.09
5.52 ± 0.08
10h
1.65 ± 0.12
29.8 ± 0.9
2.78 ± 0.20
2.65 ± 0.16
5.48 ± 0.21
10i
1.09 ± 0.09
27.7 ± 1.3
2.06 ± 0.16
1.64 ± 0.12
4.13 ± 0.29
Taxol
1.89 ± 0.09
3.73 ± 0.17
0.41 ± 0.02
4.65 ± 0.29
0.43 ± 0.03
a Results are expressed as mean ± S.D. of three independent experiments. b IC50: concentration that inhibits 50% of cell growth.
Interestingly, all the target molecules 10a–i showed selective cytotoxicity between tumor and normal liver cells, with IC50 values ranging from 22.1 to 33.9 μM against L-02 cells. Compound 10f with R1 of (CH2)3 and R2 of o-C6H4 was the most potent one against the four selected cancer cell lines. The IC50 values were 0.81, 1.73, 1.18, and 3.77 μM, which were 8.2-, 1.8-, 3.8-, 1.9-fold and 18.7-, 0.5-, 3.9-, 5.3-fold stronger than 1 and 9, respectively. The morphology effects of 10f on Bel-7402 cells are shown in Figure 2. Compound 10f also showed a good SI (selectivity index) of 36.9, while the SI values of lead oridonin and parent compound 9 were about 2.4 and 1.6, respectively. This indicated that the NO-releasing derivatives could obviously enhance the selectivity. Based on the MTT assay, most derivatives showed remarkable antiproliferative effects against Bel-7402 cells with IC50 values ranging from 0.81 to 1.91 μM. Consequently, the Bel-7402 cell line was selected for intensive mechanism studies.
Figure 2
Morphology effects of 10f on Bel-7402 (a–e, magnification: 100 times) and L-02 cells (f–j, magnification: 40 times). Cells were treated with compound 10f for 48 h, and then observed under light microscopy. (a) Negative control; (b) solvent control (DMSO); (c) cells treated with 0.125 μM 10f, (d) cells treated with 0.5 μM 10f; (e) cells treated with 2 μM 10f; (f) negative control; (g) solvent control (DMSO); (h) cells treated with 12.5 μM 10f; (i) cells treated with 25 μM 10f; (j) cells treated with 50 μM 10f.
2.3. NO-Releasing Ability
Exogenous release of nitric oxide by furoxan-based NO-donating enmein-type 6,7-seco-ent-kauranediterpenoid derivatives might contribute to the cytotoxicity. The formation of nitrite (NO2−) was a reliable proxy measure for nitric oxide, in the presence of thiol. Therefore, the levels of nitrate/nitrite in the lysates of the selective hybrids 10a, 10c, and 10f were determined at 100 μM by Griess assay over the duration of 0–60 min and measured at the time points of 10, 20, 30, 40, 50, and 60 min. As shown in Figure 3, the concentration of NO increased with time, and at all the time points measured (10, 20, 30, 40, and 50 min) 10f released more NO than 10a and 10c. At the time point of 60 min, 10a, 10c, and 10f produced 22.2, 36.2, and 33.7 μmol/L of NO, respectively.
Figure 3
Griess assay of compounds 10a, 10c and 10f measured at the time points of 0, 10, 20, 30, 40, 50, and 60 min.
2.4. Effect of Cell Cycle
In general, anticancer agents prevented cell division at various checkpoints of cell cycle, thereby decreasing the growth and proliferation of cancerous cells. To determine whether the suppression of cell growth by furoxan-based NO donor/enmein-type 6-oxo-6,7-seco-kaurane diterpenoid hybrid 10f was caused by cell-cycle effect, we further detected the DNA content of cell nuclei by flow cytometry (Figure 4). Bel-7402 cells were treated with 10f at concentrations of 1.0, 1.5, and 2.0 μM, which resulted in accumulation of 40.27%, 48.11%, and 53.34% of cells at the S phase, respectively, compared with the untreated cells. There were almost no changes of G1 phase cells, and the decline of G2 phase cells were observed of 17.32%, 8.79%, and 6.02%, respectively. The influence of cell-cycle progression at low micromolar concentrations of NO donor/enmein-type diterpenoid hybrids would make these compounds promising agents for use in combination with anticancer drugs acting at different stages of the cell cycle.
Figure 4
Influence of the cell cycle arrest of S phase by 10f in Bel-7402 cells: Bel-7402 cells were incubated with the indicated concentrations of 10f for 24 h and the cells were stained with propidium iodide (PI). Cellular DNA content, for cell cycle distribution analysis, was measured using a flow cytometer. The diagrams show the distribution of the cells according to their DNA content. The inserts give the percentages of cells in different cell cycle phases.
2.5. Induction of Apoptosis
Apoptosis is a process of programmed cell death that occurs in multicellular organisms and clears the normal aging and damaged cells. However, cancer cells usually have an abnormal ability to proliferate mainly due to defective apoptosis. Thus, activation of apoptosis can be a therapeutic method for cancer by reducing accumulation of cancer cells [47]. In order to examine the involvement of apoptosis in the loss of cancer cell viability of the most potent hybrid 10f, an annexin V-FITC/propidium iodide (PI) binding assay was carried out. Bel-7402 cells were exposed to different concentrations of 10f and percentages of apoptotic Bel-7402 cells were determined by flow cytometry. As shown in Figure 5, 10f exhibited potent dose-dependent activity in the induction of apoptosis. Treatment of Bel-7402 cells with 10f at 1.0, 1.5, and 2.0 μM, apoptotic cell rates (early and late) were 23.41%, 38.32%, and 58.80%, as compared with 8.27% in an untreated vehicle control, indicating that 10f was able to induce apoptotic cell death in Bel-7402 cells in a concentration-dependent manner.
Figure 5
Apoptosis in Bel-7402 cells by treatment with 10f: Bel-7402 cells were incubated with different concentrations of 10f for 24 h and the cells were stained with annexin V-FITC and PI, followed by flow cytometry analysis.
2.6. Effect of Mitochondrial Depolarization
Mitochondrial changes, including loss of mitochondrial membrane potential, were key events that took place during drug-induced apoptosis. Apoptotic signals could result in the loss of mitochondrial membrane potential in the process of apoptosis. The collapse of the mitochondrial transmembrane potential had been shown to promote mitochondrial permeability transition and induced the release of proapoptotic molecules, including apoptosis-inducing factors and cytochrome c, from the intermembrane space in the cytoplasm [48]. Subsequently, cytochrome c interacted with procaspase-9 to form the apoptosome leading to activation of caspase-9 and downstream effector caspases. The caspase-9 in turn activated the effector caspase-3 which on the other hand induced the apoptotic signaling cascade [49]. In the resent research of our group, we found cytochrome c played an important role in the lead compound oridonin 1-induced mitochondrion-mediated apoptosis [50]. To determine whether the apoptosis induced by furoxan-based NO-releasing enmein-type ent-kauranediterpenoid derivative 10f was through mitochondrial mediated pathway, Bel-7402 cells were incubated with different concentrations (0, 0.5, 1.5, 2.0 μM) of 10f prior to staining with the lipophilic mitochondrial probe JC-1. The number of cells with collapsed mitochondrial membrane potentials in different groups of cells was determined by flow cytometry analysis (Figure 6), yielding 3.28%, 17.76%, 33.44%, and 47.63% apoptotic cells, respectively. These results demonstrated that incubation with 10f caused mitochondrial depolarization of Bel-7402 cells.
Figure 6
Effect of 10f on the mitochondrial membrane potentials of Bel-7402 cells: Bel-7402 cells were incubated with the indicated concentrations of 10f for 48 h prior to staining with JC-1.
2.7. Effect of Apoptosis-Related Proteins
Caspases played an important role in the apoptotic signaling network, and apoptotic pathways depend on activation of caspases for the final execution of apoptosis. Therefore, caspase activity assay was performed to determine whether caspases were responsible for the apoptotic effects of 10f in Bel-7402 cells. Bcl-2 family proteins are important in the regulation of cell apoptosis and the pro-apoptotic protein Bax can be recruited to the mitochondrion and trigger cytochrome c release into cytoplasm to activate caspase-9 and -3 [51]. Anti-apoptotic protein Bcl-2 can inhibit the function of pro-apoptotic proteins by interaction and cancers with high levels of Bcl-2 show drug resistance in clinical cancer treatment [52]. It was found that there was upregulation of proapoptotic caspase-3, -8, -9, Bax, FAS, and cytochrome c molecules, and downregulation of anti-apoptotic Bcl-2 expression treated with 10f for 48 h in a concentration-dependent manner (Figure 7). The molecular mode of action revealed that 10f caused cell-cycle arrest of S phase and induced apoptosis in Bel-7402 cells through mitochondria-related caspase-dependent oxidative stress-triggered caspase 3-, 8-, and 9-dependent pathways.
Figure 7
Western blotting of 10f on the expression of apoptosis-related proteins in Bel-7402 cells. 1: negative control; 2: 2.0 μM; 3: 1.5 μM; 4: 1.0 μM.
3. Materials and Methods
3.1. Chemistry
3.1.1. General
All reagents were obtained commercially and used without further purification. Melting points were taken on an XT-4 micro melting point apparatus and uncorrected. 1H-NMR spectra were recorded with a Bruker AV-300 spectrometer (Bruker Corp., Karlsruhe, Germany) in the indicated solvents (TMS as internal standard) and 13C-NMR spectra were recorded with a Bruker AV-400 or AV-600 spectrometer (Bruker Corp.); chemical shifts were expressed as ppm against TMS as an internal reference. Splitting patterns were designed as s, singlet; d, doublet; t, triplet; m, multiplet. Mass spectra were obtained with an FTMS-2000 instrument (Thermo Fisher Scientific, Waltham, MA, USA). HRMS data were collected with an Agilent QTOF 6520 (Agilent Technologies China, Beijing, China). The reactions were monitored by thin-layer chromatography (TLC) on glass-packed precoated silica gel GF254 plates and visualized with a UV lamp. Flash column chromatography was performed using silica gel (200–300 mesh) purchased from Qingdao Haiyang Chemical Co. Ltd (Qingdao, China).
3.1.2. General Procedure to Synthesize 10
Compound 9 (72 mg, 0.2 mmol) was dissolved in 15 mL CH2Cl2 and reacted with the corresponding NO donor 7 (0.24 mmol), in addition of EDCI (0.4 mmol) and DMAP (0.02 mmol). After stirring at room temperature for 8–12 h, the mixture was poured into 15 mL 10% HCl and extracted with CH2Cl2 (3 × 10 mL). The organic layer was combined, washed sequentially with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated in vacuo. The crude product was purified by column chromatography (MeOH/CH2Cl2 1:300 v/v) to give the title compounds. The data of compounds 10a–e and 10g–i were in Supplementary Materials.Compound 10f: white solid, mp. 151–154 °C, yield 40%. 1H-NMR (CDCl3, 300 MHz), δ (ppm) 8.09 (2H, d, J = 7.5 Hz, Ar-H), 7.76 (2H, m, Ar-H), 7.65 (3H, m, Ar-H), 7.52 (2H, m, Ar-H), 6.24 (1H, s, 17-CH2), 5.86 (1H, s, 14-CH), 5.61 (1H, s, 17-CH2), 4.62 (1H, m, 1-CH), 4.58 (2H, m, -CH2), 4.47 (2H, m, -CH2), 4.06, 4.36 (each 1H, dd, JA = JB = 9.9 Hz, 20-CH2), 3.29 (1H, d, J = 9.0 Hz, 13-CH), 1.22 (3H, s, 18-CH3), 1.06 (3H, s, 19-CH3); 13C-NMR (CDCl3, 400 MHz) δ 197.37, 175.45, 167.21, 166.87, 166.09, 159.09, 147.03, 138.07, 135.87, 131.85, 131.69, 131.46, 130.94, 129.97, 129.93 (×2), 128.82, 128.73 (×2), 121.79, 110.70, 74.67, 71.51, 68.03, 61.34, 59.59, 50.90, 47.75, 46.31, 40.45, 36.40, 33.19, 32.36, 29.68, 27.97, 23.77, 23.21, 22.82, 19.19; MS (ESI) m/z: 808.3 [M + NH4]+, 790.9 [M + H]+, 825.1 [M + Cl]−; HRMS (ESI, M + NH4) m/z calcd for C39H42N3O14S: 808.2382, found: 808.2371.
3.2. Biology
3.2.1. MTT Assay
Cytotoxicity assay in vitro was employed by the MTT assay following the methodology described previously, which was performed in flat-bottomed 96-well plates. In short, exponentially growing MGC-803 cells at the log phase were added to each well at a density of 5 × 103 per well, then treated with serial dilutions of the compounds in three replicates at various concentrations (0.039–40 µg/mL). After 72 h, 20 µL of MTT solution (5 mg/mL) per well was added to each cultured medium. Then, DMSO was added to each well (150 µL/well). After 10 min at room temperature, the absorbance (OD) was read on a microplate reader at the wavelength of 490 nm (BIO-RAD Instruments Inc. 550, Hercules, CA, USA). In these experiments, taxol was used as the positive reference with the concentration of 10 µg/mL. The concentration causing 50% inhibition of cell growth (IC50) was determined. The same method was used in the test against L-02, CaEs-17, Bel-7402, and K562 cell lines.
3.2.2. Griess Assay
NO-releasing ability was determined by assaying the levels of NO2− using the Griess reagent. The levels of nitrate/nitrite formed from individual compounds were determined by nitrate/nitrite, in triplicate with 100 μM of individual compounds for 0–60 min according to the manufacturer’s instructions at the time points of 0, 10, 20, 30, 40, 50, and 60 min (Beyotime, Nanjing, China). The lysates were mixed with Griess reagent for 40 min and centrifugalized for 10 min, and then measured at 540 nm.
3.2.3. Cell Cycle Study
Progression through the cell cycle was assessed by flow cytometry DNA determination with PI. Bel-7402 cells were plated in 6-well plates (5.0 × 103 cells/well) and incubated at 37 °C for 24 h. Exponentially growing cells were then incubated with tested compound at a certain concentration in triplicate. Untreated cells (control) or cells treated with the solvent (DMSO) of the compound were included. After 48 h treatment, cells were centrifuged and fixed in 70% ethanol at 4 °C overnight and subsequently resuspended in PBS containing 100 μL RNase A and 400 μL PI. Cellular DNA content, for cell cycle distribution analysis, was measured using a flow cytometer (FACS Calibur Becton-Dickinson, Franklin Lake, NJ, USA).
3.2.4. Analysis of Cellular Apoptosis
The Bel-7402 cells were seeded in 6-well plates to grow overnight, and then treated with or without 10f at indicated concentrations in triplicate for 24 h. Cells were then washed twice in PBS and resuspended in annexin V binding buffer. Annexin V-FITC was then added and the mixture was incubated for 15 min under dark conditions at 25 °C. PI was added just prior to acquisition. Apoptosis was analyzed using annexin V and PI double-staining by flow cytometry according to the manufacturer’s instructions in order to detect apoptotic cells.
3.2.5. Mitochondrial Membrane Potential Assay
Briefly, Bel-7402 cells were incubated in triplicate with the test compound 10f (1.0, 1.5 and 2.0 μM) or vehicle for 48 h, and then washed with PBS and stained with JC-1 dye under dark conditions according to the manufacturer’s instruction (KeyGen Biotech, KGA601). The percentage of cells with healthy or collapsed mitochondrial membrane potentials was monitored by flow cytometry analysis.
3.2.6. Western Blot Analysis
Bel-7402 cells were incubated in triplicate with different doses (1.0, 1.5 and 2.0 μM) of 10f for 48 h. After the protein concentrations were determined, individual cell lysates were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (10% gel, SDS-PAGE) and transferred onto nitrocellulose membranes. After being blocked with 5% fat-free milk, the target proteins in the membranes were probed with monoclonal anti-Bax (KGA714), anti-Bcl2 (KGA715), anti-caspase 3 (KGA717), anti-caspase 9 (KGA720), anti-cyto C (KGA723), and anti-β-actin antibodies (KGA731, KeyGEN Biotech, Nanjing, China), respectively. The relative levels of each signaling event to control β-actin were determined by densimetric scanning.
4. Conclusions
In this effort, a series of NO-donating/enmein-type diterpenoid hybrids 10a–i with potent antiproliferative activities was prepared. The levels of nitrate/nitrite in the cell lysates were tested by Griess assay and the results showed that the improved antiproliferative activity could be attributed to its NO releasing to some extent. The preliminary SAR of the target compounds was discussed based on the experimental data. In all the synthetic hybrids, 10f with R1 of (CH2)3 and R2 of o-C6H4 was the most potential one. The IC50 values were 0.81, 1.73, 1.18, and 3.77 μM against Bel-7402, K562, MGC-803, and CaEs-17 humancancer cells, respectively. It also showed the best cytotoxic selectivity between tumor and normal liver L-02 cells. Furthermore, the investigation concerning the molecular mode of action revealed that 10f caused cell cycle arrest of S phase and induced apoptosis in Bel-7402 cells through mitochondria-related caspase dependent pathways. It is expected that these kinds of NO-donor/diterpenoid hybrids could provide a promising approach for the discovery of novel antitumor agents.